Treats depression. Sold as Marplan. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Isocarboxazid (sold as Marplan), first approved Jul 1, 1959, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Marplan | Part D | $299K | -14% | 75 |
| Shortage | Status | First posted | Updated |
|---|---|---|---|
| Isocarboxazid Tablet | Current | Apr 16, 2026 | Aug 6, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jul 1, 1959 | MarplanNDA 11961 ยท New molecular entity | Lifsa Drugs | 10 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA